Advaxis Receives Research Coverage.

Crystal Research Associates, LLC, Publishes Comprehensive Report

NORTH BRUNSWICK, N.J. -- Advaxis Inc., (OTCBB: ADXS, http://www.advaxis.com.), a developmental biotechnology company, receives equity research coverage from Crystal Research Associates, LLC, an independent research firm out of New York City.

The report highlights the company's patented vaccine platform that uses a live, attenuated Listeria monocytogenes ("Lm") bacterium to deliver a proprietary antigen fusion protein that stimulates a particularly effective immunological response. This unique approach is useful in the treatment of cancer, infectious disease, and allergic syndromes.

Special attention was given to the company's landmark preclinical studies data of its flagship drug candidate, Lovaxin C, which was safely administered and which resulted in a reduction of the tumor burden in over 30% of the evaluable patients. As per the data, six (6) of the fifteen (15) treated end-stage cervical cancer patients were alive in the beginning of March 2008 with a median survival of 493 days compared with 180 days historically associated with their diagnosis.

"This report clearly presents our technology and our results, which are clearly very encouraging," said Advaxis' Chief Science Officer Dr. John Rothman. "Crystal Research's report gives a useful non-technical presentation of the science and progress. Hopefully, this can help our shareholders and others understand why we are so excited about the performance of Lovaxin C in early clinical stage development."

For a copy of the full 60-page report, please visit www.crystalra.com.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC ("Crystal Research") is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research's unique and novel product, the Executive Informational Overview([R]) (EIO([R])), is free of investment ratings, target prices, and forward-looking financial models. The EIO([R]) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO([R]) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, audited financial statements, key events, and other such fundamental information. Crystal Research has offices in New York City and Delray Beach. As compensation for this report, future updates and associated printing costs, the Company compensated Crystal Research with forty thousand U.S. dollars and four hundred thousand four-year options/warrants to purchase Advaxis' stock.

About Advaxis, Inc.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes ("Lm") cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and Chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely.

Advaxis' lead Lm vaccine candidate, Lovaxin C, targets HPV-associated cervical/head and neck cancers. Current Lm vaccines in development target prostate, breast, ovarian and lung cancers. Recently, Advaxis completed a Phase I/II clinical trial. A Phase II clinical trial is planned for patients with cervical intraepithelial neoplasia (CIN). The company intends to start this study in CIN I/II patients in the summer of 2008. The Lm platform will also have applications in the fields of infectious disease and autoimmune disorders.

For further information on the Company, please visit: http://www.advaxis.com.

About Lovaxin C Vaccine

Advaxis' Listeria technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Lm, combined with Advaxis' proprietary fusion protein, has the ability to generate a robust immune response and produce an unusually strong and effective multi-level therapeutic immune response to existing cancers and other diseases.

Advaxis' Lm-based technology is mostly based on Dr. Yvonne Paterson's decade worth of work in her laboratory at the University of Pennsylvania. The Company's proprietary antigen fusion protein technology, also suppresses regulatory T cells that inhibit many vaccines in the generation of activated tumor-killing cells.

Lovaxin C was designed to treat women who have already developed cervical cancer as a result of contracting a human papilloma virus ("HPV") infection, which is the most prevalent sexually transmitted disease in the US. Current prophylactic products on the market are ineffective in treating HPV-infected women.

For further information on Lovaxin C, please visit: http://www.advaxis.com/lc.htm

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.